Tagged with Generic

Opinion Chip Davis is head of the Association for Accessible Medicines (AAM) which advocates for greater uptake of generic and biosimilar drugs in the USA. Here, Davis argues that the generics supply chain is standardized, transparent and dynamic, helping save the US healthcare system trillions of dollars.   Savings have totaled…

Egypt Dr Mohamed Mabrouk, CEO of Pharmed Healthcare, highlights how the company has evolved from only offering Hepatitis C treatment to having 112 products in the pipeline today. He also emphasises the importance of local companies for the government’s 100 Million Seha campaign, while outlining Pharmed’s future strategy including commercial partnerships…

Spain Lab Seid is a family owned pharmaceutical company based in Barcelona, specialising in branded out of patent products in the field of women’s health. Seid’s general manager, Joaquín Vilá, discusses the turnaround of the company since taking over in 2011, and the strategy behind its consolidation around gynaecology. Vila also…

Spain Marc Comas, managing director of Accord Healthcare Iberia, highlights the footprint of the company as the leading generics and biosimilars player in the Spanish hospital sector and how his early strategy when founding the affiliate has set them up for long-term success. Furthermore, he points out the dynamics of the…

USA Chip Davis of the Association for Accessible Medicines argues for greater provision for access to affordable medicines – including biosimilars – within the trade agreements that the USA is currently negotiating with its neighbours.   An American president determined to seal a trade deal. A newly elected Democratic majority with…

France Vincent Pont, president of Laboratoire Arrow, explains the company’s history, its collaboration with Aurobindo, the Indian generic pharmaceuticals group, the company’s unique positioning as a leader in the generic hospital sector, and its future growth strategies.   Generics companies need a wide portfolio to meet all of the generics needs…

France Bertrand de Lavenne, general manager of Mylan France, explains how the affiliate is positioned within the group’s operations and how the Mylan strategy is to be a key actor in connecting the health network around patient needs. De Lavenne also shares his view on the French pharmaceutical market and the…

France Pascal Brière, president of Biogaran, the leading French domestic player in generics, reflects on the development of the generic market since the 1999 Generic Substitution Act. Brière goes on to comment on Biogaran’s unique strategy of leveraging added solutions, international expansion, and biosimilars. He concludes with his thoughts on the…

USA As part of Women’s History Month, Chip Davis, president and CEO of the Association for Accessible Medicines highlights some of the most outstanding women that have worked in the generic pharmaceutical industry throughout history and pinpoints the women shaping today’s landscape for affordable and accessible medicines.   As we wrap…

France Jean-Louis Anspach, general manager of Teva France, elaborates on the affiliate’s transitional restructuring period as they make a turnaround effort in the face of group-wide challenges. Anspach goes on to explain what areas will be driving Teva forward while sharing his views on the French generic and biosimilar environment.  …

Novartis Richard Francis, CEO of Sandoz will step down at the end of the March. The abrupt announcement will fan the flames of rumours that parent company Novartis is planning a spinoff or sale for its generics arm.   This is a multi-year journey which I cannot commit to and therefore…

Japan Already established as one of the world’s leading markets for innovative and patented drugs, Japan is set to grow rapidly in 2019, partly as a result of a dramatic uptake in generics and biosimilars.   Japan’s pharmaceutical industry has long centred on strong innovation and patented drugs, but we are…